Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients

Table 1 Age, gender and clinical presentation of EBA patients

Age (years)^b
- Median	50
- Range	1–94
- Mean	46.7
- Std Dev^a	22.1
Gender^c
- Female	54%
- Male	46%
Clinical phenotype^d
- Non-MB	55%
- MB	38%
- Both	7%
Mucosal involvement (any)^e		Mucosal involvement (specific)^f
- Yes	23%	- Ocular	14.1%
- No or not indicated	77%	- Oral	90.8%
		- Esophagus	11.5%
		- Trachea/larynx	8.8%
		- Anal	3.0%
		- Genital	14.1%
Associated diseases^g		Associated inflammatory diseases^g
- Any	9.6%	- CD	0.9%
- Inflammatory	4.4%	- RA	0.5%
- Metabolic	1.3%	- Thyroiditis	0.4%
- Infection	0.9%	- UC	0.6%
- Cancer	1.9%	- Psoriasis	0.4%
- Cardiovascular	0.6%	- DTH	0.1%
- Neurology	0.5%	- Acquired hemophilia	0.1%
- Other	0.2%	- AIBD	0.6%
		- SLE	0.4%
		- Nephritis	0.1%
		- ITP	0.1%

^aAbbreviations: Std Dev standard deviation, non-MB non-mechanobullous EBA variant, MB mechanobullous EBA variant, CD Crohn’s disease, RA rheumatoid arthritis, UC ulcerative colitis, DTH delayed type hypersensitivity, AIBD autoimmune bullous dermatoses, SLE systemic lupus erythematosus, ITP idiopathic thrombocytopenic purpura
^bSpecified in 384 cases
^cSpecified in 561 cases
^dSpecified in 366 cases
^eReported in 261 cases
^fAs multiple sites were affected in some patients, the sum of specific mucosal involvement is greater than the reported 23% of patients experiencing any mucosal involvement
^gReported in 97 cases. The sum of individual associated diseases may be higher than the indicated total due to multiple associated diseases

ISSN: 1750-1172